Results of a new clinical trial show that patients with resected pancreatic ductal adenocarcinoma treated with a modified FOLFIRINOX (mF) regimen had longer survival than those treated with gemcitabine. A total of 493 patients were randomly allocated to either treatment for 24 weeks. At 33.6 months median follow-up, median disease-free survival was 21.6 months and 12.8 months (P < 0.001) and 3-year disease-free survival was 39.7% and 21.4% in the mF group and the gemcitabine group, respectively. Median overall survival was 54.4 months and 35.0 months (P = 0.003) and 3-year overall survival was 63.4% and 48.6% in the mF group and the gemcitabine group, respectively. 75.9% in the mF group and 52.9% in the gemcitabine group experienced grade 3 or 4 adverse events.
References
Original article
Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thoma, C. Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 16, 140 (2019). https://doi.org/10.1038/s41575-019-0112-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0112-3
